

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CHINA RENJI MEDICAL GROUP LIMITED

中國仁濟醫療集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock code: 648)

PROFIT WARNING ANNOUNCEMENT

AND

SUSPENSION OF TRADING

PROFIT WARNING

This announcement is made pursuant to Rule 13.09 of the Listing Rules.

The Board wishes to inform shareholders of the Company and potential investors that, based on the information currently available to the Company, the Company is expected to record a substantial loss for the financial year ended 31 December 2010 mainly due to the impairment loss recognised on assets.

The Company is in the process of finalising its annual results for the year ended 31 December 2010 which are subject to confirmation with the auditors of the Company. This profit warning announcement is only based on a preliminary assessment by the management of the Company in accordance with the information currently available to the Company.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

SUSPENSION OF TRADING

At the request of the Company, trading in the Shares was suspended with effect from 10:00 am on 18 October 2010 and shall remain suspended pending release of an announcement of the Company giving clarification to certain news released in the newspapers.

PROFIT WARNING

This announcement is made pursuant to Rule 13.09 of The Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Listing Rules").

The board of directors (the “Board”) of China Renji Medical Group Limited (the “Company”) wishes to inform shareholders of the Company and potential investors that, based on the information currently available to the Company, the Company is expected to record a substantial loss for the financial year ended 31 December 2010 mainly due to the impairment loss recognised on assets.

The Company is in the process of finalising its annual results for the year ended 31 December 2010 which are subject to confirmation with the auditors of the Company. The information contained in this profit warning announcement is only based on a preliminary assessment made by the management of the Company according to the information currently available to the Company, and is not based on any figures or information audited or reviewed by the Company’s auditors. Details of the financial information of the Company will be disclosed in the final results announcement for the financial year ended 31 December 2010, which is expected to be published on 28 March 2011. Shareholders and potential investors are advised to read the results announcement carefully.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

SUSPENSION OF TRADING

At the request of the Company, trading in the shares of the Company (the “Shares”) was suspended with effect from 10:00 am on 18 October 2010 and shall remain suspended pending release of an announcement of the Company giving clarification to certain news released in the newspapers.

By Order of the Board
China Renji Medical Group Limited
Sui Xueqing
Chairman

16 March 2011

As at the date of this announcement, the Board comprises two executive directors, namely Mr. Sui Xueqing and Mr. Wang Jianjun; three non-executive directors, namely Professor Wang Yongchang, Mr. Wu Zhenfang and Ms. Ding Nan; and two independent non-executive directors, namely Mr. Pang Wai Hong and Mr. Geng Xiaobing.